GSK now owns the global development and commercialisation rights to Empirico's COPD-targeting (siRNA) oligonucleotide, ...

Elevara’s first-in-class asset ERV001, a CDK4/6 inhibitor, is set to enter Phase II testing as an add-on treatment in RA.

Despite ADX-629 meeting all its endpoints in a Phase II trial, Aldeyra is culling the asset as part of a pipeline ...

Eli Lilly and NVIDIA will build a new supercomputer to accelerate drug discovery and shorten development cycles.

Lifecore Biomedical and PolyPeptide Laboratories have linked to deliver an end-to-end peptide manufacturing solution for US ...

European biotechs should leverage its innovation and collaborate with Asian manufacturing hubs to secure greater investment, ...

Leading clinicians, researchers & pharmaceutical innovators gathered to discuss the future of cancer treatment.

Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

MHLW of Japan has granted orphan regenerative medicine product designation to Kyowa Kirin and Orchard Therapeutics’ MLD therapy..

In the complex and challenging field of early-phase clinical trials, logistics specialists are vital. A recent podcast spoke ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

The foremost geopolitical rivalry between the US and China is increasingly being played out through trade and economic ...